In the past week, ERNA stock has gone up by 51.75%, with a monthly gain of 79.11% and a quarterly plunge of -56.18%. The volatility ratio for the week is 46.23%, and the volatility levels for the last 30 days are 23.82% for Eterna Therapeutics Inc The simple moving average for the past 20 days is 41.16% for ERNA’s stock, with a -66.46% simple moving average for the past 200 days.
Is It Worth Investing in Eterna Therapeutics Inc (NASDAQ: ERNA) Right Now?
Moreover, the 36-month beta value for ERNA is 4.34. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ERNA is 48.88M and currently, short sellers hold a 0.49% of that float. On January 22, 2025, ERNA’s average trading volume was 10.59M shares.
ERNA) stock’s latest price update
The stock price of Eterna Therapeutics Inc (NASDAQ: ERNA) has jumped by 11.06 compared to previous close of 0.42. Despite this, the company has seen a gain of 51.75% in its stock price over the last five trading days. globenewswire.com reported 2025-01-09 that World-renowned researcher brings expertise in obstetrics and gynecology from Yale University to advance Eterna’s lead indication in ovarian cancer World-renowned researcher brings expertise in obstetrics and gynecology from Yale University to advance Eterna’s lead indication in ovarian cancer
ERNA Trading at -2.06% from the 50-Day Moving Average
After a stumble in the market that brought ERNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.14% of loss for the given period.
Volatility was left at 23.82%, however, over the last 30 days, the volatility rate increased by 46.23%, as shares surge +73.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -58.13% lower at present.
During the last 5 trading sessions, ERNA rose by +51.75%, which changed the moving average for the period of 200-days by -80.05% in comparison to the 20-day moving average, which settled at $0.3322. In addition, Eterna Therapeutics Inc saw 59.49% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ERNA
Current profitability levels for the company are sitting at:
- -31.34 for the present operating margin
- -0.98 for the gross margin
The net margin for Eterna Therapeutics Inc stands at -75.14. The total capital return value is set at 8.39. Equity return is now at value -1154.18, with -149.86 for asset returns.
Based on Eterna Therapeutics Inc (ERNA), the company’s capital structure generated -2.83 points at debt to capital in total, while cash flow to debt ratio is standing at -0.51. The debt to equity ratio resting at -0.74. The interest coverage ratio of the stock is -5.12.
Currently, EBITDA for the company is -19.93 million with net debt to EBITDA at -0.75. When we switch over and look at the enterprise to sales, we see a ratio of 89.25. The receivables turnover for the company is 3.2for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.48.
Conclusion
To wrap up, the performance of Eterna Therapeutics Inc (ERNA) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
